Structure-function relationships and clinical applications of L-Asparaginases

Current Medicinal Chemistry

Volumn 17, Issue 20, 2010, Pages 2183-2195

  Labrou, N E ^a   Papageorgiou, A C ^b   Avramis, V I ^c  

^a AGRICULTURAL UNIVERSITY OF ATHENS   (Greece)

^b TURKU CENTRE FOR BIOTECHNOLOGY   (Finland)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Acute lymphoblastic leukemia; Catalytic mechanism protein crystallography; L asparaginase; Protein drug

Indexed keywords

AGAROSE; AMINO ACID; AMMONIA; ANTINEOPLASTIC AGENT; ASPARAGINASE MACROGOL; ASPARAGINE; BLEOMYCIN; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOSINE; DOXORUBICIN; ENZYME ANTIBODY; GLUTAMINASE; LIPOSOME; METHOTREXATE; MONOMER; POLYACRYLAMIDE; VINCRISTINE; ASPARAGINASE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANAPHYLACTIC SHOCK; ANAPHYLAXIS; BLOOD CLOTTING DISORDER; CATALYSIS; CLINICAL TRIAL; DISEASE SEVERITY; DRUG ACTIVITY; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG HYPERSENSITIVITY; DRUG INFORMATION; DRUG STRUCTURE; DRUG SYNTHESIS; ERRATUM; ERWINIA; ESCHERICHIA COLI; GENE SEQUENCE; HUMAN; HYDROLYSIS; HYPERLIPIDEMIA; IMMUNE RESPONSE; LYMPHOMA; MICROCAPSULE; PANCREATITIS; PROTEIN ENGINEERING; SITE DIRECTED MUTAGENESIS; TREATMENT RESPONSE; CHEMISTRY; CLINICAL TRIAL (TOPIC); ENZYME ACTIVE SITE; METABOLISM; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN TERTIARY STRUCTURE; STRUCTURE ACTIVITY RELATION;

ASPARAGINASE; CATALYTIC DOMAIN; CLINICAL TRIALS AS TOPIC; HUMANS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN ENGINEERING; PROTEIN STRUCTURE, TERTIARY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77955602245     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986710791299920     Document Type: Erratum

References (88)

1. Kidd, J.G. Regression of transplanted lymphomas induced in vivo by means of normal guinea pig serum. I. Course of transplanted cancers of various kinds in mice and rats given guinea pig serum, horse serum, or rabbit serum. J. Exp. Med., 1953, 98, 565-582.
2. Broome, J.D. Evidence that the L-Asparaginase activity of guinea pig serum is responsible for its antilymphoma effects. Nature, 1961, 191, 1114-1115.
3. Broome, J.D. Evidence that the L-asparaginase of guinea pig serum is responsible for its antilymphoma effects. II. Lymphoma6C3HED cells cultured in a medium devoid of L-asparagine lose their susceptibility to the effects of guinea pig serum in vivo. J.Exp. Med., 1963, 118, 121-148.
4. Dolowy, W.C.; Henson, D.; Cornet, J.; Sellin, H. Toxic and antineoplastic effects of L-asparaginase. Study of mice with lymphoma and normal monkeys and report on a child with leukemia. Cancer, 1966, 19, 1813-1819.
5. Oettgen, H.F.; Old, L.J.; Boyse, E.A.; Campbell, H.A.; Philips, F.S.; Clarkson, B.D.; Tallal, L.; Leeper, R.D.; Schwartz, M.K.; Kim, J.H. Inhibition of leukemias in man by L-asparaginase. Cancer Res., 1967, 27, 2619-2631
6. Ohnuma, T.; Holland, J.F.; Nagel, G.; Arneault, G.S. Effects of Lasparaginase in acute myelocytic leukemia. J. Am. Med. Assoc., 1969, 210, 1919-1921.
7. Apostolidou, E.; Swords, R.; Alvarado, Y.; Giles, F.J. Treatment of acute lymphoblastic leukaemia: a new era. Drugs, 2007, 67, 2153-2171.
8. Gaynon, P.S. Childhood acute lymphoblastic leukaemia and relapse. Br. J. Haematol., 2005, 131, 579-587.
9. Avramis, V.I.; Panosyan, E.H. Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future. Clin. Pharmacokinet., 2005, 44, 367-393.
10. Avramis, V.I.; Sencer, S.; Periclou, A.P.; Sather, H.; Bostrom, B.C.; Cohen, L.J.; Ettinger, A.G.; Ettinger, L.J.; Franklin, J.; Gaynon, P.S.; Hilden, J.M.; Lange, B.; Majlessipour, F.; Mathew, P.; Needle, M.; Neglia, J.; Reaman, G.; Holcenberg, J.S.; Stork, L. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Blood, 2002, 99, 1986-1994.
11. Muller, H.J.; Boos, J. Use of L-asparaginase in childhood ALL. Crit. Rev. Oncol. Hematol., 1998, 28, 97-113.
12. Gaynon, P.S.; Desai A.A.; Bostrom, B.C.; Hutchinson, R.J.; Lange, B.J.; Nachman, J.B.; Reaman, G.H.; Sather, H.N.; Steinherz, P.G.; Trigg, M.E.; Tubergen, D.G.; Uckun, F.M. Early response to therapy and outcome in childhood acute lymphoblastic leukemia: a review. Cancer, 1997, 80, 1717-1726.
13. Albertsen, B.K.; Schrøder, H.; Ingerslev, J.; Jakobsen, P.; Avramis, V.I.; Müller, H.J.; Carlsen, N.T.; Schmiegelow, K. Comparison of intramuscular therapy with Erwinia asparaginase and asparaginase Medac: pharmacokinetics,pharmacodynamics, formation of antibodies and influence on the coagulation system. Br. J. Haematol., 2001, 115, 983-990.
14. Appel, I.M.; Kazemier, K.M.; Boos, J. Lanvers, C.; Huijmans, J.; Veerman, A.J.; van Wering, E.; den Boer M.L.; Pieters, R. Pharmacokinetic, pharmacodynamic and intracellular effects of PEGasparaginase in newly diagnosed childhood acute lymphoblastic leukemia: results from a single agent window study. Leukemia, 2008, 22, 1665-1679.
15. Avramis, V.I.; Tiwari, P.N. Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia. Int. J. Nanomed., 2006, 1, 241-254.
16. Avramis, V.I.; Martin-Aragon, S.; Avramis, E.V.; Asselin, B.L. Pharmacoanalytical assays of Erwinia asparaginase (erwinase) and pharmacokinetic results in high-risk acute lymphoblastic leukemia (HR ALL) patients: simulations of erwinase population PK-PD models. Anticancer Res., 2007, 27, 2561-2572.
17. Wriston, J.J. Asparaginase. Methods Enzymol., 1985, 113, 608-618.
18. Wriston, J.J.; Yellin, T. L-asparaginase: a review. Adv. Enzymol., 1973, 39, 185-200.
19. Yurel, E.; Peru, D.; Wriston, J.J. On the distribution of plasma Lasparaginase. Experientia, 1983, 39, 383-385.
20. Ho, P.P.; Milikin, E.B. Multiple forms of L-asparaginase. Biochim. Biophys. Acta, 1970, 206, 196-198.
21. Michalska, K.; Jaskolski, M. Structural aspects of L-asparaginases, their friends and relations. Acta Biochim. Pol., 2006, 53, 627-640.
22. Lubkowski, J.; Wlodawer, A.; Ammon, H.L.; Copeland, T.D.; Swain, A.L. Structural characterization of Pseudomonas 7A glutaminase-asparaginase. Biochemistry, 1994, 33, 10257-10265.
23. Lubkowski, J.; Wlodawer, A.; Housset, D.; Weber, I.T.; Ammon, H.L.; Murphy, K.C.; Swain, A.L. Refined crystal structure of Acinetobacter glutaminasificans glutaminase-asparaginase. Acta Crystallogr. D, 1994, 50, 826-832.
24. Lea, P.J.; Farnden, L.; Miflin, B.J. The purification and properties of asparaginase from Lupinus species. Phytochemistry, 1979, 17, 217-222.
25. Lea, P.J.; Miflin, B.J. The Biochemistry of Plants. Academic Press, New York, 1980, 5, 290-293,
26. Lea, P.J.; Festenstein, G.; Hughes, J.S.; Miflin, B.J. An immunological and enzymological survey of asparaginase in seeds of Lupinus. Phytochemistry, 1984, 3, 511-514.
27. Dickson, J.M.J.J.; Vincze, E.; Grant, M.R.; Smith, L.A.; Rodber, K.A.; Farnden, K.J.F.; Reynolds, P.H.S. Molecular cloning of the gene encoding developing seed L-asparaginase from Lupinus angustifolius. Plant Mol. Biol., 1992, 20, 333-336.
28. Lough, T.J.; Chang, K.S.; Carne, A.; Monk, B.C.; Reynolds, P.H.; Farnden, K.J. L-asparaginase from developing seeds of Lupinus arboreus. Phytochemistry, 1992, 31, 1519-1527.
29. Lough, T.J.; Reddington, B.D.; Grant, M.R.; Hill, D.F.; Reynolds, P.H. Farnden, K.J. The isolation and characterisation of a cDNA clone encoding L-asparaginase from developing seeds of lupin (Lupinus arboreus). Plant Mol. Biol., 1992, 19, 391-399.
30. Mishalska, M.; Bujacz, G.; Jaskolski, M. Crystal structure of plant asparaginase. J. Mol. Biol., 2006, 360, 105-16.
31. Tarentino, A.L.; Maley, F. The purification and properties of a beta-aspartyl N-acetylglucosylamine amidohydrolase from hen oviduct. Arch. Biochem. Biophys., 1969, 130, 295-303.
32. Ortuño-Olea, L.; Durán-Vargas, S. The L-asparagine operon of Rhizobium etli contains a gene encoding an atypical asparaginase. FEMS Microbiol. Lett., 2000, 189, 177-182.
33. Ammon, H.L.; Weber, I.T.; Wlodawer, A.; Harrison, R.W.; Gilliland, G.L.; Murphy, K.C.; Sjolin, L.; Roberts, J. Preliminary crystal structure of Acinetobacter glutaminasificans glutaminaseasparaginase. J. Biol. Chem., 1988, 263, 150-156.
34. Swain, A.L.; Jaskólski, M.; Housset, D.; Rao, J.K.; Wlodawer, A., Crystal structure of Escherichia coli L-asparaginase, an enzyme used in cancer therapy. Proc. Natl. Acad. Sci. USA, 1993, 90, 1474-1478.
35. Aghaiypour, K.; Wlodawer, A.; Lubkowski, J. Structural basis for the activity and substrate specificity of Erwinia chrysanthemi Lasparaginase. Biochemistry, 2001, 40, 5655-5664.
36. Lubkowski, J.; Palm, G.J.; Gilliland, G.L.; Derst, C.; Röhm, K.H.; Wlodawer, A. Crystal structure and amino acid sequence of Wolinella succinogenes L-asparaginase. Eur. J. Biochem., 1996, 241, 201-207.
37. Kravchenko, O.V.; Kislitsin, Y.A.; Popov, A.N.; Nikonov, S.V.; Kuranova, I.P. Three-dimensional structures of L-asparaginase from Erwinia carotovora complexed with aspartate and glutamate Acta Crystallogr. D Biol. Crystallogr, 2008, 64, 248-256.
38. Papageorgiou, A.C.; Posypanova, G.A.; Andersson, C.S.; Sokolov, N.N.; Krasotkina, J. Structural and functional insights into Erwinia carotovora L-asparaginase. FEBS J., 2008, 275, 4306-4316.
39. Lubkowski, J.; Dauter, M.; Aghaiypour, K.; Wlodawer, A.; Dauter, Z. Atomic resolution structure of Erwinia chrysanthemi Lasparaginase. Acta Crystallogr. D Biol. Crystallogr., 2003, 59, 84-92.
40. Yao, M.; Yasutake, Y.; Morita, H.; Tanaka, I. Structure of the type I L-asparaginase from the hyperthermophilic archaeon Pyrococcus horikoshii at 2.16 angstroms resolution. Acta Crystallogr. D 2005, 61, 294-301.
41. Yun, M-K.; Nourse, A.; White, S.W.; Rock, C; Richard J. Crystal structure and allosteric regulation of the cytoplasmic Escherichia coli L-asparaginase I. J. Mol. Biol., 2007, 369, 794-811.
42. Miller, M.; Rao, J.; Wlodawer, A.; Gribskov, M., A left-handed crossover involved in amidohydrolase catalysis. Crystal structure of Erwinia chrysanthemi L-asparaginase with bound L-aspartate. FEBS Lett., 1993, 328, 275-279.
43. Ortlund, E.; Lacount, M.W.; Lewinski, K.; Lebioda, L. Reactions of Pseudomonas 7A glutaminase-asparaginase with diazo analogues of glutamine and asparagine result in unexpected covalent inhibitions and suggests an unusual catalytic triad Thr-Tyr-Glu. Biochemistry, 2000, 39, 1199-1204.
44. Palm, G.J.; Lubkowski, J.; Derst, C.; Schleper, S.; Rohm, K.H.; Wlodawer, A. A covalently bound catalytic intermediate in Escherichia coli asparaginase: crystal structure of a Thr-89-Val mutant. FEBS Lett., 1996, 390, 211-216.
45. Dodson, G.; Wlodawer, A. Catalytic triads and their relatives. Trends Biochem. Sci., 1998, 23, 347-352.
46. Dhavala, P.; Krasotkina, J.; Dubreuil, C.; Papageorgiou, A.C., Expression, purification and crystallization of Helicobacter pylori L-asparaginase. Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun., 2008, 64, 740-742.
47. Cappelletti, D.; Chiarelli, L.R.; Pasquetto, M.V.; Stivala, S.; Valentini, G.; Scotti, C. Helicobacter pylori L-asparaginase: a promising chemotherapeutic agent. Biochem. Biophys. Res. Commun., 2008, 377, 1222-1226.
48. Kotzia, G.A.; Labrou, N.E. Cloning, expression and characterization of Erwinia carotovora L-asparaginase. J. Biotechnol., 2005, 119, 309-323.
49. Derst, C.; Henseling, J.; Röhm, K.H. Engineering the substrate specificity of Escherichia coli asparaginase II. Selective reduction of glutaminase activity by amino acid replacements at position 248. Protein Sci., 2000, 9, 2009-2017.
50. Krasotkina, J.; Borisova, A.A.; Gervaziev, Y.V.; Sokolov, N.N. One-step purification and kinetic properties of the recombinant Lasparaginase from Erwinia carotovora. Biotechnol. Appl. Biochem., 2004, 39, 215-221.
51. Kotzia, G.A.; Labrou, N.E. L-Asparaginase from Erwinia Chrysanthemi 3937: cloning, expression and characterization. J. Biotechnol., 2007, 127, 657-669.
52. Moola, Z.B.; Scawen, M.D.; Atkinson, T.; Nicholls, D.J. Erwinia chrysanthemi L-asparaginase: epitope mapping and production of antigenically modified enzymes. Biochem. J., 1994, 302, 921-927.
53. Benjwal, S.; Verma, S.; Röhm, K.H.; Gursky, O. Monitoring protein aggregation during thermal unfolding in circular dichroism experiments. Protein Sci., 2006, 15, 635-639.
54. Shimizu, T.; Yamashiro, Y.; Igarashi, J.; Fujita, H.; Ishimoto, K. Increased serum trypsin and elastase-1 levels in patients undergoing L-asparaginase therapy. Eur. J. Pediatr., 1998, 157, 561-563.
55. Guo, L.; Wang, J.; Qian, S.; Yan, X.; Chen, R.; Meng, G. Construction and structural modeling of a single-chain Fv-asparaginase fusion protein resistant to proteolysis. Biotechnol. Bioeng., 2000, 70, 456-463.
56. Patel, N.; Krishnan, S.; Offman, M.N.; Krol, M.; Moss, C.X.; Leighton, C.; van Delft, F.W.; Holland, M.; Liu, J.; Alexander, S.; Dempsey, C.; Ariffin, H.; Essink, M.; Eden, T.O.; Watts, C.; Bates, P.A.; Saha, V.J. A dyad of lymphoblastic lysosomal cysteine proteases degrades the antileukemic drug L-asparaginase. Clin. Invest., 2009, 119, 1964-1973.
57. Narta, U.K.; Kanwar, S.S.; Azmi, W. Pharmacological and clinical evaluation of L-asparaginase in the treatment of leukemia. Crit. Rev. Oncol. Hematol., 2007, 61, 208-221.
58. Kotzia, G.A.; Lappa, K.; Labrou, N.E. Tailoring structure-function properties of L-asparaginase: engineering resistance to trypsin cleavage. Biochem. J., 2007, 404, 337-343.
59. Li, L.-Z.; Xie, T.-H.; Li, H.-J.; Qing, C.; Zhang, G.-H. Suna, M.-S. Enhancing the thermostability of Escherichia coli L-asparaginase II by substitution with Pro in predicted hydrogen-bonded turn structures. Enz. Microb. Technol., 2007, 41, 523-527.
60. Kotzia, G.A.; Labrou, N.E. Engineering thermal stability of Lasparaginase by in vtiro directed evolution. FEBS J., 2009, 276, 1750-1761.
61. Baran, E.T.; Ozer, N.; Hasirci, V. In vivo half life of nanoencapsulated L-asparaginase. J. Mater. Sci. Mater. Med., 2002, 13, 1113-1121.
62. Jean-Francois, J.; Fortier, G. Immobilization of L-asparaginase into a biocompatible poly(ethylene glycol)-albumin hydrogel: evaluation of performance in vivo. Biotechnol. Appl. Biochem., 1997, 26,203-212.
63. Kravtzoff, R.; Ropars, C.; Laguerre, M.; Muh, J.P.; Chassaigne, M. Erythrocytes as carriers for L-asparaginase. Methodological and mouse in-vivo studies. J. Pharm. Pharmacol., 1990, 42, 473-476.
64. Kravtzoff, R.; Desbois, I.; Lamagnere, J.P.; Muh, J.P.; Valat, C.; Chassaigne, M.; Colombat, P.; Ropars, C. Improved pharmacodynamics of L-asparaginase-loaded in human red blood cells. Eur. J. Clin. Pharmacol., 1996, 49, 465-470.
65. EMEA, Committee for Orphan Medicinal Products, Public summary of positive opinion for orphan designation of L-asparaginase encapsulated in erythrocytes for the treatment of pancreatic cancer (Doc. Ref.: EMEA/COMP/218226/2009). http://www.emea.europa.eu/
66. Wileman, T.E.; Foster, R.L.; Elliott, P.N. Soluble asparaginasedextran conjugates show increased circulatory persistence and lowered antigen reactivity. J. Pharm. Pharmacol., 1986, 38, 264-271.
67. Karsakevich, A. S.; Kinstler, O. B.; Vina, I. A.; Kashkin, A. P.; Putilova, N.E.; Merengova, L. F. Immobilization of the enzyme Lasparaginase of E. coli on polysaccharides. V. Preparation and properties of polymeric conjugates based on water-soluble CMcellulose differing by the quantitative amounts of polymer. Chem. Nat. Compd., 1987, 23, 488-492.
68. Poznansky, M.J.; Shandling, M.; Salkie, M.A.; Elliott, J.F.; Lau, E. Advantages in the use of L-asparaginase-albumin polymer as an antitumor agent. Cancer Res., 1982, 42, 1020-1025.
69. Kamisaki, Y.; Wada, H.; Yagura, T.; Nishimura, H.; Matsushima, A.; Inada, Y. Increased antitumor activity of Escherichia coli. Lasparaginase by modification with monomethoxypolyethylene glycol. Gann, 1982, 73, 470-474.
70. Uren, J.R.B.; Hargis, J.; Beardsley, P. Immunological and pharmacological characterization of poly-DL-alanyl-modified Erwinia carotovora L-asparaginase. Cancer Res., 1982, 42, 4068-4071.
71. Newsted, W. J.; Ramjeesingh, M.; Zywulko, M.; Rothstein, S.J.; Shami, E. Y. Engineering resistance to trypsin inactivation into LAsparaginase through the production of a chimeric protein between the enzyme and a protective single-chain antibody. Enz. Microb. Technol., 1995, 17, 757-764.
72. Zhang, Y.Q.; Zhou, W.L.; Shen, W.D.; Chen, Y.H.; Zha, X.M.; Shirai, K.; Kiguchi, K. Synthesis, characterization and immunogenicity of silk fibroin-L-asparaginase bioconjugates. J. Biotechnol., 2005, 120, 315-326.
73. Zhang, Y.Q.; Tao, M.L.; Shen, W.D.; Mao, J.P.; Chen, Y.H. Synthesis of silk sericin peptides-L-asparaginase (SS-ASNase) bioconjugates and their characterization. J. Chem. Technol.Biotechnol., 2006, 81, 136-145.
74. Fernandes, A.I.; Gregoriadis, G. Polysialylated asparaginase: preparation, activity and pharmacokinetics. Biochemica et Biophysica Acta., 1997, 1341, 26-34.
75. Galaev, Yu.V.; Chuplygina, E.G.; Klement'Eva, T.A. Immobilization of Citrobacter L-asparaginase in polyacrylamide gel. Voprosy Meditsinskoi Khimii., 1981, 27, 534-537.
76. Edman, P.; Nylen, U.; Sjoholm, I. Use of immobilized Lasparaginase in acrylic microparticles in an extracorporeal hollowfiber dialyzer. J. Pharmacol. Exper. Therap., 1983, 225, 164-167.
77. Huang H.; Yu, Y.; Yi, X.; Zhang, Y. Nitrogen metabolism of asparagines and glutamate in Vero cells studied by (1)H/(15)N NMR spectroscopy. Appl. Microbiol. Biotechnol., 2007, 77, 427-436.
78. Hawkins, D.S.; Park, J.R.; Thomson, B.G.; Felgenhauer, J.L.; Holcenberg, J.S.; Panosyan, E.H.; Avramis, V.I. Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated Lasparaginase therapy for children with relapsed acute lymphoblastic leukemia. Clin. Cancer Res., 2004, 10, 5335-5341.
79. Jarrar, M.; Gaynon, P.S.; Periclou, A.P.; Fu, C.; Harris, R.E.; Stram, D.; Altman, A.; Bostrom, B.; Breneman, J.; Steele, D.; Trigg, M.; Zipf, T.; Avramis, V.I. Asparagine depletion after pegylated E. coli asparaginase treatment and induction outcome in children with acute lymphoblastic leukemia in first bone marrow relapse: a Children's Oncology Group study (CCG-1941). Pediatr Blood Cancer, 2006, 47, 141-146.
80. Douer, D.; Yampolsky, H.; Cohen, L.J.; Watkins, K.; Levine, A.M.; Periclou, A.P.; Avramis, V.I. Pharmacodynamics and safety of intravenous Pegaspargase during remission induction in adultsaged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. Blood, 2007, 109, 2744-2750.
81. Panosyan, E.H.; Grigoryan, R.S.; Avramis, I.A.; Seibel, N.L.; Gaynon, P.S.; Siegel, S.E.; Fingert, H.J.; Avramis, V.I. Deamination of glutamine is a prerequisite for optimal asparagine deamination by asparaginases in vivo (CCG-1961). Anticancer Res., 2004, 24, 1121-1125.
82. Panosyan, E.H.; Seibel, N.L.; Martin-Aragon, S.; Gaynon, P.S.; Avramis, I.A.; Sather, H.; Franklin, J.; Nachman, J.; Ettinger, L.J.; La, M.; Steinherz, P.; Cohen, L.J.; Siegel, S.E.; Avramis, V.I.; Children's Cancer Group Study CCG-1961. J Pediatr Hematol Oncol., 2004, 26, 217-26.
83. Panosyan, E.H.; Seibel, N.L.; Martin-Aragon, S.; Gaynon, P.S.; Avramis, I.A.; Sather, H.; Franklin, J.; Nachman, J.; Ettinger, L.J.; La, M.; Steinherz, P.; Cohen, L.J.; Siegel, S.E.; Avramis, V.I.; Comment in: J. Pediatr. Hematol. Oncol., 2004, 26, 333-335.
84. Lee, C.; Gianos, M.; Klaustermeyer, W.B. Diagnosis and management of hypersensitivity reactions related to common cancer chemotherapy agents. Ann. Allergy Asthma Immunol. 2009, 102, 179-187.
85. Weiss, R.B. Hypersensitivity reaction to cancer chemotherapy. Semin. Oncol., 1982, 9, 5-12.
86. Werner, A.; Röhm, K.-H.; M􀀃ller, H.-J. Mapping of B-cell epitopes in E. coli asparaginase II, an enzyme used in leukemia treatment. Biol. Chem., 2005, 386, 535-540,
87. Hrushesky, W.J.; Slavik, M.; Penta, J.; Muggia, F. The other asparaginase. Med. Pediatr. Oncol., 1976, 2, 441-442.
88. Albertsen, B.K.; Schrøder, H.; Jakobsen, P.; Müller, H.J.; Carlsen, N.T.; Schmiegelow, K. Monitoring of Erwinia asparaginase therapy in childhood ALL in the Nordic countries. Br. J. Clin. Pharmacol., 2001, 52, 433-437.